The company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio
Glenmark Pharmaceuticals, US (Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for diclofenac sodium gel, three per cent, the generic version of Solaraze gel, three per cent of Fougera Pharmaceuticals.
According to IMS Health, sales data for the 12 month period ending July 2016, the Solaraze gel, three per cent market achieved annual sales of approximately $297.9 million.